Table 4.
HF medication in the study population, divided into quartiles based on BNP
|
BNP quartile |
1 |
2 |
3 |
4 |
p value |
|---|---|---|---|---|---|
| Range (ng/L) |
10-51 |
52-102 |
103-191 |
192-4200 |
|
| (n = 100) | (n = 101) | (n = 101) | (n = 100) | ||
| ACE inhibitors/ARBs n (%) |
14 (14) |
20 (19.8) |
20 (19.8) |
28 (28) |
0.11 |
| Beta-blockers n (%) |
14 (14) |
31 (30.7) |
45 (44.6) |
54 (54) |
<0.001 |
|
a, b, c, e | |||||
| Spironolactone n (%) |
9 (9) |
4 (4) |
7 (6.9) |
7 (7) |
0.56 |
| Digoxin n (%) |
2 (2) |
1 (1) |
13 (12.9) |
14 (14) |
<0.001 |
|
b, c, d, e | |||||
| Furosemide/loop diuretics n (%) |
27 (27) |
39.6 (40) |
36 (35.6) |
50 (50) |
0.009 |
|
c | |||||
| Loop diuretics with simultaneous ACE inhibitor/ARB treatment n (%) | 6 (6) | 15 (14.9) | 13 (12.9) | 20 (20) |
0.034 |
| c |
Significant difference between BNP quartiles 1–4, is presented as:
1 and 2: a.
1 and 3: b.
1 and 4: c.
2 and 3: d.
2 and 4: e.
3 and 4: f.